Aly-Khan A Lalani, Anil Kapoor, Naveen S Basappa, Bimal Bhindi, Georg A Bjarnason, Dominick Bosse, Rodney H Breau, Christina M Canil, Luisa M Cardenas, Vincent Castonguay, Claudia Chavez-Munoz, William Chu, Shaan Dudani, Jeffrey Graham, Daniel Y C Heng, Christian Kollmannsberger, Jean-Baptiste Lattouf, Scott Morgan, M Neil Reaume, Patrick O Richard, Anand Swaminath, Simon Tanguay, Lori A Wood, Luke T Lavallée
INTRODUCTION: Several recent randomized trials evaluated the impact of adjuvant immune checkpoint inhibitor (ICI)-based therapy on post-surgical outcomes in renal cell carcinoma (RCC), with disparate results. The objective of this consensus statement is to provide data-driven guidance regarding the use of ICIs after complete resection of clear-cell RCC in a Canadian context. METHODS: An expert panel of genitourinary medical oncologists, urologic oncologists, and radiation oncologists with expertise in RCC management was convened in a dedicated session during the 2022 Canadian Kidney Cancer Forum in Toronto, Canada...
May 2023: Canadian Urological Association Journal